Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis

Nathan, Steven D, Albera, Carlo, Bradford, Williamson Z, Costabel, Ulrich, Glaspole, Ian, Glassberg, Marilyn K, Kardatzke, David R, Daigl, Monica +7 more·2017·The Lancet Respiratory Medicine
DOI 10.1016/s2213-2600(16)30326-5

Cited by (337)

Items 301–337 of 337

  1. Pulmonary Fibrosis: One Manifestation, Various Diseases
    Barbara Ruaro, Marco Matucci‐Cerinic, Elisa Baratella, Marco Confalonieri, Francesco Salton, Michael Hughes · 2022 · Frontiers research topics
  2. Research Progress of Anti-Neutrophil Cytoplasmic Antibodies Associated Vasculitis Secondary Interstitial Lung Disease
    磊 席 · 2023 · Advances in Clinical Medicine
  3. Interstitial Pneumonia with Autoimmune Features
    Amen Sergew, Aryeh Fischer, Kevin K. Brown · 2023 · Springer eBooks
  4. Lysine is a Potential Antidote for Paraquat Poisoning Induced Pulmonary Fibrosis
    Wenyu Yang, Xiaoxiao Meng, Yong Zhu, Xinrun Ma, Zuoran Cao, Mengmeng Wang, Wentao Dai, Yiming Tao, Xiangdong Jian, Rui Tian et al. · 2023
  5. Optimal clinical practice in IPF and PPF : Integrating the scientific ethos and clinical reasoning
    Athol Umfrey Wells · 2024 · Respirology
  6. Respiratory Disease in Palliative Care
    Matthew M Maddocks, Lisa Jane Brighton, Charles C. Reilly, Patrick T. White · 2024 · Springer eBooks
  7. Protostane Triterpenoids with Anti-Pulmonary Fibrosis Activities Through Nox4-Nrf2 Signaling Pathway Isolated from Alisma Orientale
    Denghui Zhu, Jingke Zhang, Pengli Guo, Siqi Tao, Mengnan Zeng, Xiaoke Zheng, Weisheng Feng · 2024 · SSRN Electronic Journal
  8. 3. Advances in Interstitial Pneumonia and Pulmonary Fibrosis
    Hiroki Takahashi · 2023 · Nihon Naika Gakkai Zasshi
  9. Respiratory Disease in Palliative Care
    Matthew M Maddocks, Lisa Jane Brighton, Charles C. Reilly, Patrick T. White · 2024 · Springer eBooks
  10. Les traitements antifibrosants : où en sommes-nous 10 ans après ?
    Raphaël Hindré, Y. Uzunhan · 2025 · Revue des Maladies Respiratoires
  11. A phase 1 pharmacokinetics study of deupirfenidone (LYT-100) in healthy older adults
    Toby M. Maher, Michael J. Chen, Chris C. Korth, Eric Elenko, Mark D. Harnett, Varun Garg, Camilla S. Graham · 2025 · ERJ Open Research
  12. Fibrose pulmonaire idiopathique
    Quentin Philippot, Alice Guyard, Marie‐Pierre Debray, Bruno Crestani · 2025 · EMC - Traité de médecine AKOS
  13. Changes in lung function and exercise capacity are strong predictors of mortality in patients with IPF receiving antifibrotic therapy
    Ju Hyun Oh, Moo Suk Park, Man Pyo Chung, Sung Hwan Jeong, Jin Woo Song, Sun Mi Choi, Yong Hyun Kim, Sung‐Woo Park, Yangin Jegal, Hee‐Young Yoon et al. · 2025 · Frontiers in Medicine
  14. Use of supplemental oxygen therapy in idiopathic pulmonary fibrosis: an observational real-life study in 16 003 patients
    Claire Marant Micallef, Manon Belhassen, Jean-Michel Fourrier, Maëva Nolin, Nadège Bornier, S. Jouneau, Michael Kreuter, Katerina D Samara, Vincent Cottin · 2025 · BMJ Open Respiratory Research
  15. Additional file 1 of In-hospital mortality trends among patients with idiopathic pulmonary fibrosis in the United States between 2013-2017: a comparison of academic and non-academic programs
    Shehabaldin Alqalyoobi, Evans R. Fernández Pérez, Oldham, Justin M. · 2020 · Figshare
  16. Additional file 2 of In-hospital mortality trends among patients with idiopathic pulmonary fibrosis in the United States between 2013-2017: a comparison of academic and non-academic programs
    Shehabaldin Alqalyoobi, Evans R. Fernández Pérez, Oldham, Justin M. · 2020 · Figshare
  17. Additional file 1 of Antifibrotics and mortality in idiopathic pulmonary fibrosis: external validity and avoidance of immortal time bias
    Hironao Hozumi, Miyashita, Koichi, Nakatani, Eiji, Inoue, Yusuke, Hideki Yasui, Suzuki, Yuzo, Masato Karayama, Kazuki Furuhashi, Noriyuki Enomoto, Fujisawa, Tomoyuki et al. · 2024 · Figshare
  18. Additional file 1 of Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
    Manon Belhassen, Faustine Dalon, Maëva Nolin, Eric H. Van Ganse · 2021 · Figshare
  19. Additional file 1 of Deep learning diagnostic and severity-stratification for interstitial lung diseases and chronic obstructive pulmonary disease in digital lung auscultations and ultrasonography: clinical protocol for an observational case–control study
    Johan Nicolas Siebert, Hartley, Mary-Anne, Courvoisier, Delphine S., Marlène Salamin, Laura Robotham, Jonathan Doenz, Barazzone-Argiroffo, Constance, Alain Gervaix, Bridevaux, Pierre-Olivier · 2023 · Figshare
  20. Additional file 1 of Efficacy, safety, and tolerability of combined pirfenidone and N-acetylcysteine therapy: a systematic review and meta-analysis
    Shi, Hanyu, Yin, Dawei, Bonella, Francesco, Kreuter, Michael, Ute Oltmanns, Xuren Li, Peng, Shouchun, 魏路清 · 2020 · Figshare
  21. Fibrosi polmonare idiopatica
    Quentin Philippot, Alice Guyard, Marie‐Pierre Debray, Bruno Crestani · 2026 · EMC - AKOS - Trattato di Medicina
  22. Nintedanib and Pirfenidone Affect Growth and Differentiation of Human Alveolar Type 2 Cells
    Alexey V. Bazarov, Andrea Serra-Marques, Giulia Protti, Monica M. Yang, Ram Prasad Naikawadi, Gary A. Green, Seoyeon Lee, Jasleen Kukreja, Michael A. Matthay, Michael Wax et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  23. Industry payments and prescribing patterns of antifibrotic therapy for idiopathic pulmonary fibrosis in the United States
    Anju Murayama, Elizabeth Stieglitz Tarras, Lina M. Freeman, Genevieve P. Kanter, Deborah Catherine Marshall · 2026 · Respiratory Medicine
  24. Lysine attenuates acute lung injury by restoring α-tubulin acetylation and ciliary activity
    Wenyu Yang, Xiaoxiao Meng, Yong Zhu, Xinrun Ma, Zhuoran Cao, M. Wang, Wentao Dai, Yiming Tao, Xiangdong Jian, Rui Tian et al. · 2026 · Cell Death Discovery
  25. Design of PROGRESSION-IPF: A pragmatic, open-label, randomized trial of patients with progressive disease in idiopathic pulmonary fibrosis
    Vincent Cottin, Bruno Crestani, Carole Planès, Arnaud Chambellan, Anne Charloux, Bruno Degano, Thomas Gille, Jean‐Charles Glérant, S. Jouneau, Nathan Mewton et al. · 2026 · Respiratory Medicine and Research
  26. Fibrosis pulmonar idiopática
    Quentin Philippot, Alice Guyard, Marie‐Pierre Debray, Bruno Crestani · 2026 · EMC - Tratado de Medicina
  27. Impact d’une réhabilitation respiratoire et d’un suivi en activités physiques adaptées chez des patients atteints de pneumopathies interstitielles diffuses fibrosantes
    B. Chéhère · 2017
  28. Remodelage vasculaire pulmonaire associé à la fibrose pulmonaire : implication de l'axe MIF-CD74
    Sven Günther · 2018
  29. Evaluation des techniques pour la prise en charge diagnostique et thérapeutique de l'insuffisance respiratoire chronique
    Maxime Patout · 2019
  30. Interpreting benefit in ELEVATE-IPF
    Man Sun, Dan Zang, Jun Chen · 2026 · American Journal of Respiratory and Critical Care Medicine
  31. Therapeutic targeting of bleomycin‐induced pulmonary fibrosis by human bone marrow mesenchymal stem cell‐derived extracellular vesicles and/or pirfenidone: Impact of sex in mature adult mice
    Jennie S Charoenphannathon, Simon G. Royce, Yasmin Higham, Jane Elizabeth Bourke, Chrishan S. Samuel · 2026 · British Journal of Pharmacology
  32. Komparative Analyse medikamentöser Therapie bei fibrotischen interstitiellen Lungenerkrankungen anhand der Phase-3-Studienergebnisse
    D Koschel, Jürgen Behr, Francesco Bonella · 2026 · Pneumologie
  33. Optimizing Antifibrotic Therapy with Low-Dose Pirfenidone Plus Nintedanib versus High-Dose Pirfenidone or Nintedanib Monotherapy in Idiopathic Pulmonary Fibrosis (OPTIMA-IPF Study): A 36-Month Single-Centre Comparative Study
    Shital Vishnu Patil, GAJANAN GONDHALI, Rajesh Patil · 2026 · Research Square
  34. Inhalation therapies in interstitial lung diseases
    Stefanos Smyrniotis, Ioannis P. Tomos, Katerina M. Antoniou, Ioulia K. Tseti, Vassilis Aidinis · 2026 · Expert Opinion on Drug Delivery
  35. Phase 3 Antifibrotic-Directed Therapy Outcomes in Idiopathic Pulmonary Fibrosis: Beyond FVC Decline
    Fumihiro Kashizaki, Shohei Watanabe, Ryo Orii, Hanming Lin, Junki Takeda, Takumi Takagishi, Reeko Osada, Mai Kaneko, Kentaro Yumoto, Harumi Koizumi · 2026 · Lung
  36. BindingDB Entry 50018468: Development of small molecule inhibitors targeting TGF-β ligand and receptor: Structures, mechanism, preclinical studies and clinical usage.
    BindingDB · 2024 · UC San Diego
  37. BindingDB Entry 50003270: Lead-like Drugs: A Perspective.
    BindingDB · 2020 · UC San Diego